Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsIntas pharma

    Intas Pharma

    Jump to

    • USFDA pulls up Intas Pharma for manufacturing lapses at Ahmedabad plant

      In a warning letter to the company's CEO and MD Nimish Chudgar, the US Food and Drug Administration (USFDA) has pointed out various manufacturing lapses at the Matoda-Sanand, Ahmedabad-based facility.

    • US FDA hits Intas Pharma with warning letter; notes data integrity lapses at Ahmedabad plant

      The regulator noted that visual inspectors manipulated particle and other defect counts on records to keep the finished product batches within rejection limits

    • EXCLUSIVE: Complaints prompt Intas to recall batch of biosimilar Razumab in India

      Intas said it is undertaking a detailed analysis on reports of inflammation and has advised doctors to avoid using the product, meant to treat an age-related eye condition, from this specific batch.

    • Teva assets complementary to Intas' business: CEO

      Ahmedabad based Intas Pharma which is a closely held company buys Tava's European assets for USD 764 million in an all cash deal. CNBC-TV18's Nisha Poddar spoke with Binish Chudgar, MD of Intas Pharma.

    • Eye acqusitions in US, Europe; to list in 3-5 yrs: Intas Pharma

      Intas is looking at more acquisitions in US and Europe to strengthen its three main areas of operations - oral solid tablet, oncology, and differentiated patent products, the company's MD Binish Chudgar said.

    • Intas Pharma IPO likely, plans to raise Rs 1000-1200 cr

      Intas Pharma is likely to file Draft Red Herring Prospectus (DRHP) with Securities and Exchange Board of India (Sebi), in the next two weeks. It has decided to revive its IPO plan.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347